Log In
Print
BCIQ
Print
Print this Print this
 

Laminin-111 (PRT-01)

  Manage Alerts
Collapse Summary General Information
Company Prothelia Inc.
DescriptionLaminin-111 protein replacement therapy
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD); Treat limb girdle muscular dystrophy 2I (LGMD2I); Treat merosin-deficient congenital muscular dystrophy type 1A (MDC1A)
Regulatory Designation

U.S. - Orphan Drug (Treat merosin-deficient congenital muscular dystrophy type 1A (MDC1A));
U.S. - Orphan Drug (Treat Duchenne muscular dystrophy (DMD))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today